Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard® gel: a randomized, cross-over, pharmacokinetic study

Contraception

Volumn 79, Issue 2, 2009, Pages 150-154

  Brache, Vivian ^a   Croxatto, Horacio ^b,d   Kumar, Narender ^c   Sitruk Ware, Regine ^c   Cochón, Leila ^a   Schiappacasse, Veronica ^b   Sivin, Irving ^c   Muñoz, Carla ^b   Maguire, Robin ^c   Faundes, Anibal ^a  

^a PROFAMILIA   (Dominican Republic)

^b Instituto Chileno de Medicina Reproductiva   (Chile)

^c POPULATION COUNCIL   (United States)

^d UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

Author keywords

Emergency contraception; LNG; Pharmacokinetics; Pre coital contraceptive gel; Vaginal absorption

Indexed keywords

CARRAGEENAN; LEVONORGESTREL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG ABSORPTION; FEMALE; HUMAN; MALE; REPRODUCIBILITY; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE;

ABSORPTION; ADMINISTRATION, INTRAVAGINAL; ADULT; CARRAGEENAN; COITUS; CONTRACEPTIVE AGENTS, FEMALE; CROSS-OVER STUDIES; FEMALE; HUMANS; LEVONORGESTREL; MALE; MIDDLE AGED; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 58149149754     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.08.010     Document Type: Article

References (20)

1. UNAIDS WHO AIDS epidemic update: special report on HIV/AIDS: December 2006
2. Baba M., Nakajima M., Schols D., Pauwels R., Balzarini J., and De Clercq E. Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res 9 (1988) 335-343
3. Pearce-Pratt R., and Phillips D.M. Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of HIV-1. Biol Reprod 54 (1996) 173-182
4. Zacharopoulos V.R., and Phillips D.M. Vaginal formulations of carrageenan protect mice from herpes simplex virus infection. Clin Diag Lab Immunol 4 (1997) 465-468
5. Jerse A.E. Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice. Infect Immun 67 (1999) 5699-5708
6. Maguire R., Bergman N., and Phillips D.M. Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytoxicity, antibacterial properties, and sperm immobilization. Sex Transm Dis 28 (2001) 259-265
7. Spencer S.E., Valentin-Bon I.E., Whaley K., and Jerse A.E. Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model. J Infect Dis 189 (2004) 410-419
8. Elias C.J., Coggins C., Alvarez F., et al. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan. Contraception 56 (1997) 387-389
9. Coggins C., Blanchard K., Alvarez F., et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm Inf 76 (2000) 480-483
10. Kilmarx P.H., van de Wilgert J.H., Chaikummao S., et al. Safety and acceptability of the candidate microbicide Carraguard in Thai women: finding from a Phase II clinical trial. J Acquir Immune Defic Syndr 43 (2006) 327-334
11. Von Hertzen H., Piaggio G., Ding J., et al. World Health Organization. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 360 (2002) 1803-1810
12. Sitruk-Ware R., Brache V., Maguire R., et al. Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for "dual protection" contraception. Contraception 75 (2007) 454-460
13. Brache V., Croxatto H., Sitruk-Ware R., et al. Effect of a single vaginal administration of levonorgestrel in Carraguard gel on the ovulatory process: a potential candidate for "dual protection" emergency contraception. Contraception 76 (2007) 111-116
14. Trial Shows Anti-HIV microbicide is safe, but does not prove it effective. Population Council News Release. Johannesburg, South Africa and New York, NY. February 2008.
15. Bebb R.A., Anawalt B.D., Khristensen R.B., Paulsen C.A., Bremner W.J., and Matsumoto A.M. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 81 (1996) 757-762
16. Kamischke A., Ploger D., Verherm S., von Eckardstein S., von Eckardstein A., and Nieschlag E. Intramuscular testosterone undecanoate with or without oral levonorgestel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol 53 (2000) 43-53
17. Anawalt B.D., Bebb R.A., Bremner W.J., and Matsumoto A.M. A lower dosage levonorgestrel and testoterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl 20 (1999) 407-414
18. Gonzalo I.T., Swerdloff R.S., Nelson A.L., et al. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab 87 (2002) 3562-3572
19. Pollanen P., Nikkanen V., and Huhtaniemi I. Combination of subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel for male hormonal contraception. Int J Androl 24 (2001) 369-380
20. Piaggio G., von Hertzen G., Grimes D.A., and VanLook P.F. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 353 (1999) 721